Aziyo Biologics, which makes regenerative medical products for various tissue types, raised $50 million by offering 2.9 million shares at $17, within the range of $16 to $18. Insiders have indicated an interest in purchasing up to $20 million of the offering. At pricing, the company commands a fully diluted market value of $177 million.
Aziyo Biologics plans to list on the Nasdaq under the symbol AZYO. Piper Sandler and Cowen acted as joint bookrunners on the deal.
